Mergers & Acquisitions
By The Online Investor Staff, updated Fri., Apr. 26, 12:13 AM
Slide #87. Nuvation Bio Inc. — AnHeart Therapeutics Ltd.
Acquirer: |
Nuvation Bio Inc. (NYSE:NUVB) |
Acquiree: |
AnHeart Therapeutics Ltd. |
Details: |
Nuvation Bio Inc. (NYSE:NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer. With the acquisition's completion, AnHeart is now a wholly-owned subsidiary of Nuvation Bio. |
Nuvation Bio is a clinical-stage biopharmaceutical company developing therapeutic candidates focused on treating patients with cancers. Co. is developing six wholly owned compounds that have resulted from its drug discovery and development programs, which include: NUV-422, a selective small molecule inhibitor of cyclin-dependent kinase; NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor; NUV-569, an oral small molecule selective inhibitor of Wee1 kinase, a regulator of DNA damage repair; and a drug-drug conjugate platform, which is a therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates.
NUVB SEC Filing Email Alerts Service
Open the NUVB Page at The Online Investor »
Company Name: |
Nuvation Bio Inc |
Website: |
www.nuvationbio.com |
Sector: |
Biotechnology |
Number of ETFs Holding NUVB: |
14 |
Total Market Value Held by ETFs: |
$32.35M |
Total Market Capitalization: |
$584.00M |
% of Market Cap. Held by ETFs: |
5.54% |
|
Open the NUVB Page at The Online Investor (in a new window) »
|
April 26, 2024 12:13 AM Eastern
Strong Buy (3.83 out of 4)
73rd percentile
|
|